With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.
The U.S. government named 15 drugs that will be subject to the second round of price negotiations by Medicare, including ...
5d
The Wall Street CEO discussed growing confidence among business leaders after his bank’s strong fourth-quarter report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback